3KYK
Crystal structure of li33 Igg1 Fab
3KYK の概要
| エントリーDOI | 10.2210/pdb3kyk/pdb |
| 関連するPDBエントリー | 3KYM |
| 分子名称 | Heavy Chain Li33 IgG1, Light Chain Li33 IgG1, SULFATE ION, ... (4 entities in total) |
| 機能のキーワード | antibody, immune system |
| 由来する生物種 | Homo sapiens (human) 詳細 |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 48110.50 |
| 構造登録者 | |
| 主引用文献 | Pepinsky, R.B.,Silvian, L.,Berkowitz, S.A.,Farrington, G.,Lugovskoy, A.,Walus, L.,Eldredge, J.,Capili, A.,Mi, S.,Graff, C.,Garber, E. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci., 19:954-966, 2010 Cited by PubMed Abstract: Monoclonal antibodies (Mabs) are a favorite drug platform of the biopharmaceutical industry. Currently, over 20 Mabs have been approved and several hundred others are in clinical trials. The anti-LINGO-1 Mab Li33 was selected from a large panel of antibodies by Fab phage display technology based on its extraordinary biological activity in promoting oligodendrocyte differentiation and myelination in vitro and in animal models of remyelination. However, the Li33 Fab had poor solubility when converted into a full antibody in an immunoglobulin G1 framework. A detailed analysis of the biochemical and structural features of the antibody revealed several possible reasons for its propensity to aggregate. Here, we successfully applied three molecular approaches (isotype switching, targeted mutagenesis of complementarity determining region residues, and glycosylation site insertion mutagenesis) to address the solubility problem. Through these efforts we were able to improve the solubility of the Li33 Mab from 0.3 mg/mL to >50 mg/mL and reduce aggregation to an acceptable level. These strategies can be readily applied to other proteins with solubility issues. PubMed: 20198683DOI: 10.1002/pro.372 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (3.2 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






